No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.

Research output: Contribution to journalArticle

Abstract

To compare the cancer risk of cladribine and other disease-modifying drugs (DMDs) in trials of people with relapsing multiple sclerosis (pwRMS).

Details

Authors
  • Julia Pakpoor
  • Giulio Disanto
  • Daniel R Altmann
  • Sue Pavitt
  • Benjamin P Turner
  • Monica Marta
  • Gunnar Juliusson
  • David Baker
  • Jeremy Chataway
  • Klaus Schmierer
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Neurology
Original languageEnglish
Pages (from-to)e158
JournalNeurology: Neuroimmunology and NeuroInflammation
Volume2
Issue number6
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes

Total downloads

No data available